Underuse of aspirin in type 2 diabetes mellitus: Prevalence and correlates of therapy in rural Canada

Clinical Therapeutics

Volumn 26, Issue 3, 2004, Pages 439-446

  Klinke, Jennifer A ^a   Johnson, Jeffrey A ^b,c   Guirguis, Lisa M ^c   Toth, Ellen L ^a,c   Lee, T K ^a   Lewanczuk, Richard Z ^a   Majumdar, Sumit R ^a,b,c  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c INSTITUTE OF HEALTH ECONOMICS   (Canada)

Author keywords

Aspirin therapy; Guideline adherence; Prevention; Type 2 diabetes mellitus; Underuse

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPYRIDAMOLE; TICLOPIDINE;

ADULT; AGED; ARTICLE; CANADA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEMOGRAPHY; DRUG COST; DRUG SAFETY; DRUG USE; EVIDENCE BASED MEDICINE; FEMALE; HEALTH CARE QUALITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PREVALENCE; RURAL POPULATION; SELF REPORT;

EID: 1842502988     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(04)90040-9     Document Type: Article

References (23)

1. Moss SE, Klein R, Klein BE. Cause-specific mortality in a population-based study of diabetes. Am J Public Health. 1991;81:1158-1162.
2. Koskinen SV, Reunanen AR, Martelin TP, Valkonen T. Mortality in a large population-based cohort of patients with drug-treated diabetes mellitus. Am J Public Health. 1998;88:765-770.
3. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434-444.
4. Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: The Framingham study. Circulation. 1979;59:8-13.
5. Haffner SM, Lehto S, Rönnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229-234.
6. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383-393.
7. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.
8. Colwell JA, for the American Diabetes Association. Aspirin therapy in diabetes. Diabetes Care. 2003;26(Suppl 1):S87-S88.
9. Meltzer S, Leiter L, Daneman D, et al. 1998 clinical practice guidelines for the management of diabetes in Canada. Canadian Diabetes Association. CMAJ. 1998;159(Suppl 8):S1-S29.
10. Majumdar SR, Johnson JA, Guirguis LM, et al. Rationale and design for the DOVE Study: A prospective, controlled trial of an intervention to improve care for patients with diabetes in rural communities. Can J Diabetes Care. 2001;25:173-179.
11. Grant RW, Cagliero E, Murphy-Sheehy P, et al. Comparison of hyperglycemia, hypertension, and hypercholesterolemia management in patients with type 2 diabetes. Am J Med. 2002;112:603-609.
12. McFarlane SI, Jacober SJ, Winer N, et al. Control of cardiovascular risk factors in patients with diabetes and hypertension at urban medical centers. Diabetes Care. 2002;25:718-723.
13. Ware J Jr, Kosinski M, Keller SD. A 12-item short-form health survey: Construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34:220-233.
14. Hosmer DW, Lemeshow S. Assessing the fit of the model. In: Applied Logistic Regression. 1st ed. New York: Wiley; 1989:135-173.
15. Schapansky LM, Johnson JA, Majumdar SR, et al. The burden of pharmacotherapy for patients with type 2 diabetes in Northern Alberta - Data from the DOVE Study. Can J Clin Pharmacol. 2001;8:22. Abstract.
16. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. JAMA. 1992;268:1292-1300.
17. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351:1755-1762.
18. Harpaz D, Gottlieb S, Graff E, et al. Effects of aspirin treatment on survival in non-insulin-dependent diabetic patients with coronary artery disease. Israeli Bezafibrate Infarction Prevention Study Group. Am J Med. 1998;105:494-499.
19. Aspirin therapy in diabetes. American Diabetes Association. Diabetes Care. 1997;20:1772-1773.
20. Majumdar SR, Gurwitz JH, Soumerai SB. Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease. J Gen Intern Med. 1999;14:711-717.
21. Rolka DB, Fagot-Campagna A, Narayan KM. Aspirin use among adults with diabetes: Estimates from the Third National Health and Nutrition Examination Study. Diabetes Care. 2001;24:197-201.
22. Krein SL, Vijan S, Pogach LM, et al. Aspirin use and counseling about aspirin among patients with diabetes. Diabetes Care. 2002;25:965-970.
23. Faragon JJ, Waite NM, Hobson EH, et al. Improving aspirin prophylaxis in a primary care diabetic population. Pharmacotherapy. 2003;23:73-79.